ADJUVANT TAMOXIFEN IN THE MANAGEMENT OF OPERABLE BREAST CANCER: THE SCOTTISH TRIAL
- 1 July 1987
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 330 (8552), 171-175
- https://doi.org/10.1016/s0140-6736(87)90762-8
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Anti‐estrogen treatment of postmenopausal breast cancer patients with high risk of recurrence: 72 months of life‐table analysis and steroid hormone receptor statusWorld Journal of Surgery, 1985
- The Christie Hospital Tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma - 7-yr resultsEuropean Journal of Cancer and Clinical Oncology, 1985
- ADJUVANT TAMOXIFEN THERAPY AND RECEPTOR LEVELSThe Lancet, 1985
- Oestrogen receptor concentration in primary breast cancer and axillary node metastasesBreast Cancer Research and Treatment, 1981
- Oestrogen-receptor status and endocrine therapy of breast cancer: response rates and status stabilityBritish Journal of Cancer, 1981
- Tamoxifen in advanced breast cancerCancer Treatment Reviews, 1978
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977
- Combination Chemotherapy as an Adjuvant Treatment in Operable Breast CancerNew England Journal of Medicine, 1976
- L-Phenylalanine Mustard (L-PAM) in the Management of Primary Breast CancerNew England Journal of Medicine, 1975